

Applicants: Bernard F. Erlanger and Bi-Xing Chen
Serial No: 10/618,179
Filed: July 11, 2003
Page: 2

Amendment to the claims:

Please replace the claims with the listing of claims below.

1. (currently amended) A composition of matter comprising an antibody and a peptide moiety, wherein the peptide moiety comprises ~~an amino acid residue having a nitrogen-containing side chain~~ L-arginine and wherein the peptide is covalently bound to a carbohydrate moiety on a CH2 domain of the antibody.
2. (cancelled)
3. (cancelled)
4. (currently amended) The composition of claim 1, wherein the peptide moiety is selected from the group consisting of poly-L-arginine ~~[[,]] poly L-lysine and poly L-ornithine.~~
5. (original) The composition of claim 1, wherein the peptide moiety comprises poly-L-arginine.
6. (cancelled)
7. (cancelled)
8. (original) The composition of claim 1, wherein the peptide moiety has a molecular weight of between about 11 kD and about 16 kD.
9. (original) The composition of claim 8, wherein the peptide moiety has a molecular weight of about 13 kD.

Applicants: Bernard F. Erlanger and Bi-Xing Chen
Serial No: 10/618,179
Filed: July 11, 2003
Page: 3

10. (original) The composition of claim 1, wherein the peptide moiety is ten or fewer amino acid residues in length.
11. (original) The composition of claim 10, wherein the peptide is an octa-peptide.
12. (cancelled)
13. (original) The composition of claim 1, wherein the peptide moiety is at least ten amino acid residues in length.
14. (original) The composition of claim 13, wherein the peptide moiety has a length of between about 10 amino acid residues and about 100 amino acid residues.
15. (original) The composition of claim 14, wherein the peptide moiety has a length of between about 25 amino acid residues and about 75 amino acid residues.
16. (original) The composition of claim 15, wherein the peptide moiety is about 68 amino acids in length.
17. (original) The composition of claim 1, wherein the antibody is a monoclonal antibody.
18. (original) The composition of claim 1, wherein the antibody is a polyclonal antibody.
19. - 36. (cancelled)
37. (original) A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable

Applicants: Bernard F. Erlanger and Bi-Xing Chen
Serial No: 10/618,179
Filed: July 11, 2003
Page: 4

carrier.

38. (original) A kit comprising the composition of claim 1 and instructions for use.

39. (cancelled)

40. (cancelled)